Outlook Therapeutics, Inc.

OTLK

US69012T3059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:15:03 2024-05-17 pm EDT			5-day change	1st Jan Change
7.715 ^USD	+5.25%		+1.72%	-2.16%

May. 15	Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
May. 13	Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	MT

Outlook Therapeutics, Inc. Announces Termination of Kenneth M. Bahrt as Chief Medical Officer

April 26, 2019 at 05:01 pm EDT

On April 23, 2019, Kenneth M. Bahrt, M.D. was terminated as the Chief Medical Officer of Outlook Therapeutics, Inc. with immediate effect in connection with the elimination of his position.

Latest news about Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15	CI
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	May. 13	MT
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	Apr. 14	CI
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	Apr. 14	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Outlook Therapeutics Shares Rise After BTIG Upgrade	Mar. 27	MT
BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	Mar. 27	MT
Outlook Therapeutics Reports Secondary Share Offering	Mar. 25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 22	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	Mar. 22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	Mar. 22	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 22	CI
Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors	Mar. 17	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	Mar. 12	MT
North American Morning Briefing : S&P 500 Seen -2-	Feb. 16	DJ
Outlook Therapeutics Shares Climb Following Upgrade by Chardan	Feb. 15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	Feb. 15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	Feb. 15	MT
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
North American Morning Briefing :Stock Futures -2-	Feb. 14	DJ
Outlook Therapeutics Doses First Patient in Eye Disease Study	Jan. 31	MT
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	Jan. 31	CI
North American Morning Briefing : Intel Drags Down -2-	Jan. 26	DJ
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	Jan. 25	MT

Chart Outlook Therapeutics, Inc.

Duration

Period

More charts

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.33 USD

Average target price

39.86 USD

Spread / Average Target

+443.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OUTLOOK THERAPEUTICS, INC.	-2.16%	172M
MODERNA, INC.	+34.27%	50.85B
IQVIA HOLDINGS INC.	+0.26%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.81%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.99%	19.13B
BIO-TECHNE CORPORATION	+8.74%	13.05B
MEDPACE HOLDINGS, INC.	+27.06%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.38%	12.08B

Other Biotechnology & Medical Research